Showing results (61-70 of 660) with videos related to
Sort By:
Pageof 66
Leukemia & Lymphoma|November 5, 2021
Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatmentAislinn Macklin-Doherty, Michael Jones, Penny Coulson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2004
A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancerRohit Lal, James Dickson, David Cunningham, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2002
Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancerNick Maisey, Ian Chau, David Cunningham, et al.BMC Cancer|January 22, 2015
Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experienceKhurum Khan, Clare Peckitt, Francesco Sclafani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trialAlicia F C Okines, Sue E Ashley, David Cunningham, et al.Current Oncology (Toronto, Ont.)|September 26, 2025
Clinical and Molecular Profiling of Colorectal Cancer: A Comprehensive Cohort Study of BRAF-Mutated Cases from a Tertiary CentreJulia Freckelton, Justin Mencel, Iris Levink, et al.Expert Opinion on Investigational Drugs|June 21, 2014
Investigational therapies targeting the ErbB family in oesophagogastric cancerSing Yu Moorcraft, Ian ChauPharmacogenomics|June 14, 2021
Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinomaCaroline Yk Fong, Ian ChauExpert Opinion on Investigational Drugs|November 3, 2021
Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trialsByung Woog Kang, Ian ChauESMO Open|August 21, 2020
Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancerByung Woog Kang, Ian ChauPageof 66